As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Evoke Pharma Inc. The largest reported stake is Klein Roger M.'s, at 10.5%. 5 filings are on record since September 8, 2025 (Schedule 13D, November 12, 2025).
Sell to companies like Evoke Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Nantahala Capital Management, LLC · Percent: 0% · SCHEDULE 13D/A
- · Holder: Morgan Stanley · Percent: 0% · SCHEDULE 13G/A
- · Holder: Klein Roger M. · Percent: 10.5% · SCHEDULE 13D
- · Holder: Nantahala Capital Management, LLC · Percent: 15.99% · SCHEDULE 13D/A
- · Holder: Morgan Stanley · Percent: 10.5% · SCHEDULE 13G
Evoke Pharma Inc has 5 Schedule 13D or 13G filings on record since 2025-09-08. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 10.5% | 163,000 | SCHEDULE 13D, 2025-11-12 | 2025-11-04 | |
| 0% | 31 | SCHEDULE 13G/A, 2025-12-05 | 2025-11-30 | |
| Nantahala Capital Management, LLC | 0% | 0 | SCHEDULE 13D/A, 2025-12-19 | 2025-12-17 |
Holding shares or following this stake? See who's behind Evoke Pharma Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Evoke Pharma Inc and the records around it.
Evoke Pharma Inc elsewhere on the record
- Acquisition Dec 2025
Companies that share a holder
- Nantahala Capital Management, LLC also filed stake reports on 70 other companies: Research Alliance Corp III (Oct 2026), ADC Therapeutics SA (Aug 2026), Anteris Technologies Global Corp. (Aug 2026)
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
Watch Evoke Pharma Inc
Get an email when Evoke Pharma Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Evoke Pharma Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Evoke Pharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evoke Pharma Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Nantahala Capital Management, LLC
Item 4 is amended by the addition of the following: As disclosed by the Issuer in a Current Report on Form 8-K (the "Closing 8-K") filed with the U.S. Securities and Exchange Commission on December 17, 2025, on the same date Parent completed the acquisition of the Company, by causing Merger Sub to merge with and into the Company (the "Merger") pursuant to the Merger Agreement without a vote of the Company stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the "DGCL"). At the Effective Time, Merger Sub was merged with and into the Company, the separate existence of Merger Sub ceased and the Company continued as a wholly owned subsidiary of Parent (the "Surviving Corporation"). At the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (other than Shares (i) owned by the Company, Parent, Merger Sub or any direct or indirect wholly owned subsidiary of Parent or Merger Sub prior to the Effective Time, (ii) irrevocably accepted for payment pursuant to the Offer, or (iii) held by any stockholder who is entitled to demand and has properly and validly demanded their statutory right of appraisal of such Shares in accordance with, and in compliance in all respects with, Section 262 of the DGCL), including each Shares then beneficially owned by the Reporting Persons, was automatically cancelled and extinguished and converted into the right to receive an amount in cash equal to the $11.00 per …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-19; the filing has the rest
Klein Roger M.
On November 4, 2025, Mr. Klein acquired, or in his capacity as trustee caused the Krieger Charitable Trust (the "Charitable Trust") to acquire, all 163,000 shares of Common Stock of the Issuer currently owned by the Reporting Persons (the "Klein Shares"). This acquisition came after the Issuer announced in a Current Report on Form 8-K (the "Merger 8-K") filed with the U.S. Securities and Exchange Commission on November 4, 2025, that on November 3, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger") with QOL Medical, LLC, a Delaware limited liability company ("Parent"), and certain of its affiliates (together with Parent, "QOL"), pursuant to which QOL will commence a tender offer (the "Offer") to acquire all of the outstanding shares of Common Stock for $11.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (the "Offer Price"). Mr. Klein is not affiliated with QOL, did not have any access to insider or non-public information, and acquired, or caused to be acquired, the Klein Shares pursuant to his personal investment strategy and the Charitable Trust's investment strategy. The Reporting Persons do not seek to take an active role in the Merger, have no present activist intent with respect to the Merger and did not intend to acquire a notable block of the Issuer's outstanding Common Stock. Mr. Klein intends to sell (or cause to be sold) a small number of the Klein Shares, on November 6, 2025 to reduce his …The first part of Item 4 of the SCHEDULE 13D filed 2025-11-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-08 | Morgan Stanley | 10.5% | SCHEDULE 13G |
| 2025-11-04 | Nantahala Capital Management, LLC | 15.99% | SCHEDULE 13D/A |
| 2025-11-12 | Klein Roger M. | 10.5% | SCHEDULE 13D |
| 2025-12-05 | Morgan Stanley | 0% | SCHEDULE 13G/A |
| 2025-12-19 | Nantahala Capital Management, LLC | 0% | SCHEDULE 13D/A |
Questions about who owns Evoke Pharma Inc
Who owns Evoke Pharma Inc?
On this page, one holder's latest ownership filing reports 5% or more of Evoke Pharma Inc: Klein Roger M. (10.5%, Schedule 13D, filed 2025-11-12).
When did Klein Roger M. buy into Evoke Pharma Inc?
The filings give report dates, not purchase dates. The earliest filing from Klein Roger M. on this page is the Schedule 13D, filed 2025-11-12, reporting 10.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Evoke Pharma Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 17, 2025 | Acquired by QOL Medical, LLC | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Evoke Pharma Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.